The challenges of treating early-stage TNBC

Heather McArthur, MD, MPH, UT Southwestern Medical Center, Dallas, TX, talks on a clinical controversies session at the San Antonio Breast Cancer Symposium (SABCS) 2022 surrounding the challenges associated with treating early-stage triple-negative breast cancer (TNBC) and discusses the new standard-of-care established from the Phase III KEYNOTE-522 (NCT03036488) trial. KEYNOTE-522 had shown statistically significant and clinically meaningful pathological complete response (pCR) and event-free survival (EFS) rates in patients with early triple-negative breast cancer (TNBC) with the addition of pembrolizumab to neoadjuvant chemotherapy. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.